Direct Meds Tirzepatide Review: Cost, Oral Option & Honest Verdict (2026)

Direct Meds is a compounded telehealth pharmacy (launched 2024) that is unusual in offering an oral/sublingual tirzepatide route in addition to standard injectable, on an all-inclusive fee. This review covers what Direct Meds is, what it dispenses, the compounded-versus-brand distinction, its pricing, and the important verification caveats. We disclose an affiliate relationship with Direct Meds; it never changes our scoring, and every fact here comes from what the company states about its own program.

What Direct Meds is

Direct Meds is a compounded-only telehealth pharmacy, launched in 2024, that offers both oral/sublingual and injectable tirzepatide, plus compounded semaglutide. Fees are described as all-inclusive with no separate membership. Two honest caveats up front: the figures below are stated by the company rather than confirmed on a live public price page during our review, and the brand operates across multiple domains — so we present its numbers with that caveat rather than as independently verified.

The compounded-vs-brand question

Two very different products share the name tirzepatide:

• •Brand tirzepatide is Eli Lilly's FDA-approved Zepbound (weight management, obstructive sleep apnea) and Mounjaro (type 2 diabetes) — the exact molecule and dose studied in the pivotal trials.
• •Compounded tirzepatide is pharmacy-made, not FDA-approved, and was not the product tested in those trials.

Everything Direct Meds dispenses is compounded. That distinction matters more in 2026: the FDA declared the tirzepatide shortage resolved in October 2024, and the enforcement discretion that permitted routine large-scale compounding ended in early 2025 (around February 18, 2025 for 503A pharmacies, March 19, 2025 for 503B outsourcing facilities) — the full timeline is in our guide to whether compounded tirzepatide is still legal in 2026. The oral/sublingual route in particular lacks the injectable's robust absorption and efficacy evidence.

What Direct Meds costs in 2026

Per the company, compounded tirzepatide runs roughly $224/month sublingual or ~$399/month injectable, with compounded semaglutide around $179–$297/month (an intro promo around $147). Fees are described as all-inclusive with no separate membership, which is a plus for predictability. The important caveat is that these are company-stated figures we could not confirm on a live public price page, so treat them as a starting point to verify directly rather than a firm quote.

For context, LillyDirect sells brand Zepbound self-pay vials at roughly $299–$449/month depending on dose (prices effective February 23, 2026; 28-day supply). For the full cash-price picture, see our Zepbound cost and savings guide.

How the care model holds up

Direct Meds' strengths are a rare oral/sublingual tirzepatide option in addition to injectable, all-inclusive pricing with no separate membership fee, and both molecules available. The trade-offs are significant: the tirzepatide is compounded and not FDA-approved; the pricing is company-stated and could not be independently verified on a live page; it is a newer operator (2024) with an ambiguous footprint across multiple domains; and the states served are not disclosed. Those verification gaps are the main reason to proceed carefully and confirm everything in writing. Tirzepatide carries labeled warnings for acute pancreatitis, gallbladder disease, and a boxed thyroid C-cell tumor warning — see our guides on Zepbound side effects, the gallbladder risk, and the thyroid cancer warning.

Does the drug work? (Separate from the provider)

Separate the provider from the medication, and the brand molecule from a compounded copy. Brand tirzepatide's efficacy is trial-grade: in the 72-week SURMOUNT-1 trial, adults without diabetes lost on average roughly 15% to 21% of body weight across the 5–15 mg doses, versus about 3% on placebo¹; against semaglutide in SURMOUNT-5, tirzepatide produced significantly greater weight loss — about 20% versus 14%². Those results were established with the brand injectable molecule; compounded versions — and especially oral/sublingual formats — were never tested in those trials, so the trial efficacy cannot be assumed to transfer. The full picture is in our tirzepatide evidence guide and our look at oral tirzepatide.

The honest verdict

Direct Meds is worth a look mainly if you specifically want a rare oral/sublingual tirzepatide option on an all-inclusive fee — and you are comfortable with a compounded, non-FDA-approved product and with the verification gaps. Those gaps are the real reservation: company-stated pricing we could not confirm on a live page, a newer operator with an ambiguous multi-domain footprint, and undisclosed states served. Verify everything in writing before paying. If you prefer a provider with transparent, verifiable pricing and included support, weigh CoreAge Rx; if you specifically want brand tirzepatide, price it against LillyDirect. See our best tirzepatide providers ranking and best place to get Zepbound online roundup.